C
INBX icon

Covestor’s Inhibrx INBX Stock Holding History

Covestor’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
+1
New +$74 ﹤0.01% 2507
2024
Q4 		– Sell
-1,666
Closed -$26K – 2468
2024
Q3 		$26K Buy
+1,666
New +$23.4K 0.02% 1121

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Covestor's INBX Position: Q1 2026 in Review

Covestor opened a new position in Inhibrx (INBX) in Q1 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2507 among its holdings. This is a return to the name: Covestor previously reported a position in INBX as recently as Q3 2024.

Covestor first reported a position in INBX in Q3 2024 and has held it in 2 quarters since. The position peaked at $26K in Q3 2024. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Covestor held 1 share of Inhibrx worth $0 as of Q1 2026.
  • Inhibrx was a new Covestor position in Q1 2026.
  • Inhibrx made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2507 holding.
  • Covestor first reported a position in Inhibrx in Q3 2024 and has held it in 2 quarters since.
  • Covestor's Inhibrx position peaked at $26K in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.